In short
This article examines recent clinical trials investigating the use of Doxorubicin Hydrochloride, Liposomal in treating various types of cancer. Doxorubicin Hydrochloride, Liposomal is a chemotherapy drug encapsulated in tiny fat particles called liposomes, which allows it to target cancer cells more effectively while potentially reducing side effects. The trials discussed explore its efficacy in breast cancer, ovarian cancer, and other malignancies, often in combination with other treatments.
What is DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL?
DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL is a chemotherapy medication used to treat various types of cancer. It is a special formulation of the drug doxorubicin, which is encased in tiny fat bubbles called liposomes. This liposomal form allows the medication to be delivered more effectively to cancer cells while potentially reducing some side effects.
The medication is also known by several other names, including:
- Liposomal doxorubicin
- Pegylated liposomal doxorubicin
- Caelyx
- Doxil
How does it work?
DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL works by interfering with the DNA in cancer cells, preventing them from growing and dividing. The liposomal formulation helps the medication stay in the bloodstream longer and accumulate more effectively in tumor tissues.
What is it used for?
This medication is used to treat several types of cancer, including:
- Ovarian cancer: Particularly in cases where the cancer has returned or progressed after initial platinum-based chemotherapy
- Breast cancer: Especially in advanced or metastatic cases
- Multiple myeloma: A type of blood cancer
- AIDS-related Kaposi's sarcoma: A type of cancer that causes patches of abnormal tissue to grow under the skin
How is it administered?
DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL is typically given as an intravenous infusion. This means it is delivered directly into your bloodstream through a vein. The infusion is usually given over a period of time, which can range from 30 minutes to several hours, depending on the specific dosage and treatment plan.
Dosage information
The dosage of DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL can vary depending on several factors, including the type of cancer being treated, the patient's body surface area, and their overall health. Some common dosage ranges include:
- 40-50 mg/m² (milligrams per square meter of body surface area) every 4 weeks
- Up to 75 mg/m² in some cases
The total treatment duration can last up to 24 months in some cases, but this can vary based on the individual treatment plan and response to therapy.
Potential side effects
Like all medications, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL can cause side effects. Some potential side effects include:
- Fatigue
- Nausea and vomiting
- Hair loss
- Mouth sores
- Skin reactions (rash, redness, or peeling on hands and feet)
- Low blood cell counts (which can increase risk of infection or bleeding)
- Heart problems (in rare cases)
It's important to discuss potential side effects with your healthcare provider, as they can provide guidance on managing these effects and may adjust your treatment if necessary.
Precautions and considerations
Before receiving DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, it's important to inform your healthcare provider about:
- Any allergies or previous reactions to medications
- All other medications, supplements, or herbal products you're taking
- Any history of heart problems
- Pregnancy or plans to become pregnant
- Breastfeeding
Regular monitoring, including blood tests and heart function tests, may be necessary during treatment.
Ongoing research
DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL continues to be studied in various clinical trials. Some ongoing research includes:
- Investigating its use in combination with other cancer treatments
- Exploring its effectiveness in different types of cancer
- Studying ways to further reduce side effects and improve patient outcomes
For example, one study is comparing the combination of DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL with carboplatin to other standard treatments in patients with recurrent ovarian cancer.
If you're interested in participating in a clinical trial or learning more about ongoing research, discuss this with your healthcare provider or visit reputable clinical trial registries for more information.